We are confident that the synergies this merger creates will accelerate our ability to discover and optimize biotherapeutic drugs for cancer, inflammatory diseases, and critical care, as well as diabetes and obesity - areas where proteins, such as monoclonal antibodies, are of great therapeutic benefit.